AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9890490 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g daily)
Number of subjects: 30
Study 9890490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7675959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 ml 95% USP alcohol/kg body weight
Number of subjects: 0
Study 7675959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml 95% USP alcohol/kg body weight
Number of subjects: 0
Study 7675959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 ml 95% USP alcohol/kg body weight
Number of subjects: 0
Study 7675959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.135 ml 95% USP alcohol/kg body weight (active placebo)
Number of subjects: 0
Study 7675959 — intervention group
Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 0
Study 2288827 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 21
Study 2288827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 92511 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 CCA units of purified subunit vaccine
Number of subjects: 186
Study 92511 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,400 CCA units of whole-virus vaccine
Number of subjects: 186
Study 92511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 92511 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 CCA units of whole-virus vaccine
Number of subjects: 186
Study 30523381 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (C- group)
Number of subjects: 81
Study 30523381 — intervention group
Group type: COMPARATOR
Intervention: Capeox without Celecoxib (C+ group)
Number of subjects: 81
Study 28706173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reflection program (6 sessions over 6 weeks)
Number of subjects: 38
Study 28706173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 26467994 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL pathway intervention with tailored QoL diagnosis and therapy, including QoL profile and expert report with treatment recommendations.
Number of subjects: 220
Study 26467994 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up care attending the guideline recommendations for colorectal cancer without profile or expert report.
Number of subjects: 220
Study 23406545 — intervention group
Group type: EXPERIMENTAL
Intervention: NK₁ receptor antagonist aprepitant
Number of subjects: 18
Study 23406545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19962291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wormwood (Artemisia absinthium) 3x750mg dried powdered for 6 weeks
Number of subjects: 20
Study 19962291 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study 19962291 — intervention group
Group type: EXPERIMENTAL
Intervention: Wormwood (Artemisia absinthium)
Number of subjects: 20
Study 18244958 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured three session programme at age 8‐15 months, co‐led by well child providers and a parenting expert.
Number of subjects: 733
Study 18244958 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 733
Study 16864616 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 1200
Study 16864616 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 1200
Study 14638493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% resiquimod
Number of subjects: 41
Study 14638493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% resiquimod
Number of subjects: 41
Study 14638493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% resiquimod
Number of subjects: 41
Study 14638493 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 41
Study 14638493 — intervention group
Group type: EXPERIMENTAL
Intervention: All resiquimod doses
Number of subjects: 41
Study 10651836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp with infusion of 20 glucose (30% enriched with 13C‐1‐glucose)
Number of subjects: 8
Study 10651836 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of 13C MRS to determine total muscular glucose content
Number of subjects: 8
Study 10651836 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with troglitazone
Number of subjects: 8
Study 9079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant follicle stimulating hormone (rFSH; Puregon)
Number of subjects: 1000
Study 9079411 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH or human menopausal gonadotrophins
Number of subjects: 1000
Study 1298221 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 480
Study 1298221 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 480
Study 6575025 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional APF gel
Number of subjects: 0
Study 6575025 — intervention group
Group type: EXPERIMENTAL
Intervention: Thixotropic gel
Number of subjects: 0
Study 6575025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluronic-based fluoride gel
Number of subjects: 0
Study 30077128 — intervention group
Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled knee
Number of subjects: 50
Study 30077128 — intervention group
Group type: COMPARATOR
Intervention: Non-microprocessor-controlled knee
Number of subjects: 50
Study 28167467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermidoc cream
Number of subjects: 100
Study 28167467 — intervention group
Group type: COMPARATOR
Intervention: PolymixinB-bacitrin ointment
Number of subjects: 100
Study 26329480 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 4 water-in-oil emulsion
Number of subjects: 40
Study 23312684 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 19
Study 23312684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 19
Study 23312684 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study 21908986 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackknife position
Number of subjects: 40
Study 21908986 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 40
Study 18469232 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) providing 800 kcal/d
Number of subjects: 147
Study 16565030 — intervention group
Group type: EXPERIMENTAL
Intervention: Four interviews and dialogues about pain with a female doctor (Group A)
Number of subjects: 45
Study 16565030 — intervention group
Group type: COMPARATOR
Intervention: Usual consultations with a male doctor (Group B)
Number of subjects: 45
Study 16565030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 14743958 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced iron
Number of subjects: 32
Study 14743958 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron
Number of subjects: 32
Study 14743958 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 32
Study 14743958 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between reduced and electrolytic iron
Number of subjects: 32
Study 10955337 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educational and exercise program (6 weekly sessions of 2 hours)
Number of subjects: 105
Study 10955337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 105
Study 8962564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 20
Study 8962564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1362205 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (15 mg/day)
Number of subjects: 32
Study 1362205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2413282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil administered orally (160 mg) before cytostatic treatment
Number of subjects: 9
Study 2413282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil administered orally (160 mg) after cytostatic treatment
Number of subjects: 9
Study 31010904 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29153933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial window
Number of subjects: 130
Study 29153933 — intervention group
Group type: COMPARATOR
Intervention: Mediastinal window
Number of subjects: 130
Study 27467290 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for catheterization
Number of subjects: 350
Study 27467290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 350
Study 24403824 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid artificial cardiac pacing (RACP)
Number of subjects: 168
Study 24403824 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 168
Study 22002482 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-on formula with polydextrose and galactooligosaccharides (PDX/GOS)
Number of subjects: 133
Study 22002482 — intervention group
Group type: COMPARATOR
Intervention: Cow's‐milk‐based follow‐on formula (control)
Number of subjects: 133
Study 20152241 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (n = 857)
Number of subjects: 1707
Study 20152241 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (n = 850)
Number of subjects: 1707
Study 20152241 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1707
Study 18714713 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to women for screening in a randomized clinical trial
Number of subjects: 4131
Study 18714713 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for study participation
Number of subjects: 4131
Study 16908215 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-lesson (9-month) intervention program to reduce TV viewing time
Number of subjects: 164
Study 14600516 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified maintenance therapy (SMT)
Number of subjects: 1449
Study 14600516 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (part of SMT)
Number of subjects: 1449
Study 14600516 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (part of SMT)
Number of subjects: 1449
Study 14600516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (part of SMT)
Number of subjects: 1449
Study 14600516 — intervention group
Group type: COMPARATOR
Intervention: Continued protease inhibitor (PI) therapy
Number of subjects: 1449
Study 10912659 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro disaccharidase activity measurement
Number of subjects: 54
Study 10912659 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo hydrolysis of lactose, sucrose, and palatinose
Number of subjects: 54
Study 10912659 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo lactase and sucrase deficiency
Number of subjects: 54
Study 10912659 — intervention group
Group type: EXPERIMENTAL
Intervention: Histomorphometric assessment of jejunal biopsy specimens
Number of subjects: 54
Study 8645051 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH plus propranolol
Number of subjects: 6
Study 8645051 — intervention group
Group type: COMPARATOR
Intervention: rhGH
Number of subjects: 6
Study 1824248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX)
Number of subjects: 77
Study 1824248 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 77
Study 6850612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (Nocardia rubra cell wall skeleton, 400 micrograms, intradermal injection weekly for the first month and monthly thereafter)
Number of subjects: 302
Study 6850612 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control group)
Number of subjects: 302
Study 30211721 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mirror and extracorporeal shock wave therapy (ESWT)
Number of subjects: 120
Study 30211721 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 120
Study 30211721 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 120
Study 30211721 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 120
Study 29364083 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hand cooling (1H)
Number of subjects: 12
Study 29364083 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hand cooling (2H)
Number of subjects: 12
Study 29364083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling jacket (CJ)
Number of subjects: 12
Study 29364083 — intervention group
Group type: COMPARATOR
Intervention: No cooling (NC)
Number of subjects: 12
Study 29364083 — intervention group
Group type: COMPARATOR
Intervention: Cognitive performance (Stroop Colour-Word test)
Number of subjects: 12
Study 27321342 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (2.5mg/day)
Number of subjects: 82
Study 27321342 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 82
Study 24331545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS), single 20-minute treatment
Number of subjects: 63
Study 24331545 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 63
Study 24331545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS)
Number of subjects: 63
Study 22176629 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 50 mg
Number of subjects: 35
Study 22176629 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 100 mg
Number of subjects: 35
Study 22176629 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg
Number of subjects: 35
Study 22176629 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 35
Study 22176629 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 2 mg
Number of subjects: 35
Study 20482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichomonas prevalence
Number of subjects: 198
Study 20482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia prevalence
Number of subjects: 198
Study 20482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis prevalence
Number of subjects: 198
Study 20482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonorrhea prevalence
Number of subjects: 198
Study 20482337 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for trichomonas
Number of subjects: 198
Study 17373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemia (high homocysteine level >15 micromol/L)
Number of subjects: 92
Study 17373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemia
Number of subjects: 92
Study 17373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal Crohn's disease
Number of subjects: 92
Study 17373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration of at least 5 years
Number of subjects: 92
Study 15829804 — intervention group
Group type: COMPARATOR
Intervention: Topical natamycin 5%
Number of subjects: 100
Study 15829804 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical itraconazole 1%
Number of subjects: 100
Study 12102671 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam, 500 mg, twice daily
Number of subjects: 18
Study 12102671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10208788 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and support by a nurse during hospital stay and a home visit within a week of discharge
Number of subjects: 179
Study 10208788 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 179
Study 10208788 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and support by a nurse
Number of subjects: 179
Study 7605860 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg t.d.s. for 4 weeks
Number of subjects: 23
Study 7605860 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 23
Study 2369474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical application of cephalotin in saline solution
Number of subjects: 200
Study 2369474 — intervention group
Group type: COMPARATOR
Intervention: Saline solution only (control group)
Number of subjects: 200
Study 454027 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 113
Study 454027 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 113
Study 31743300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB)
Number of subjects: 30
Study 31743300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 30
Study 31743300 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin (ALB)
Number of subjects: 30
Study 31743300 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 30
Study 31104507 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 0
Study 31104507 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 0
Study 31104507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 27915105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h Time in Bed for 4 nights)
Number of subjects: 0
Study 27915105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (30h total)
Number of subjects: 0
Study 27915105 — intervention group
Group type: COMPARATOR
Intervention: Well-rested (9h Time in Bed)
Number of subjects: 0
Study 27915105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss (both partial and total)
Number of subjects: 0
Study 27915105 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual false memory task
Number of subjects: 0
Study 25573410 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea
Number of subjects: 213
Study 24016143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health quality improvement program (SHQIP)
Number of subjects: 68
Study 24016143 — intervention group
Group type: COMPARATOR
Intervention: Usual STI clinical care
Number of subjects: 68
Study 21813191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 90
Study 19559427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL cyanoacrylate injection (group A)
Number of subjects: 91
Study 19559427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL cyanoacrylate injection (group B)
Number of subjects: 91
Study 17055681 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 39
Study 17055681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 39
Study 15118585 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic and open gastric banding
Number of subjects: 50
Study 11578673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dosing (SDD) of antidepressants
Number of subjects: 22
Study 11578673 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dosing (MDD) of antidepressants
Number of subjects: 22
Study 9573431 — intervention group
Group type: EXPERIMENTAL
Intervention: Light social drinkers
Number of subjects: 0
Study 9573431 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate social drinkers
Number of subjects: 0
Study 8147945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg slow release tablet, Aprical long)
Number of subjects: 88
Study 8147945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 8147945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 88
Study 3260059 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking therapy
Number of subjects: 43
Study 3260059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna therapy
Number of subjects: 43
Study 3260059 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 43
Study 30390443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 92
Study 30390443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 26972105 — intervention group
Group type: EXPERIMENTAL
Intervention: Coactivation Group (CG) - where muscle coactivation was increased intentionally.
Number of subjects: 34
Study 26972105 — intervention group
Group type: COMPARATOR
Intervention: Non-Coactivation Group (NCG) - control group with no intentional increase in muscle coactivation.
Number of subjects: 34
Study 26039600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791
Study 26039600 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1791
Study 23782948 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate, large isocaloric doses, duration 8 weeks
Number of subjects: 0
Study 23782948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice protein isolate, large isocaloric doses, duration 8 weeks
Number of subjects: 0
Study 23782948 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21744346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IP) - 10 min ischemia, 10 min reperfusion
Number of subjects: 160
Study 21744346 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Portal Clamping (IPC) - 15 min ischemia, 5 min reperfusion
Number of subjects: 160
Study 19332353 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based renal sympathetic denervation
Number of subjects: 50
Study 19332353 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated patients)
Number of subjects: 50
Study 16384587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional technique involving self-cueing to recall specific autobiographical experiences
Number of subjects: 30